Richard Burr: “As Ranking Member Burr pointed out, we need to continue to examine the Rating Schedule.”

I hope to receive that response soon.

Are you beginning to see the pattern as to why a plan is important? This has been a well-orchestrated event up to this point.

What does it mean for a small company when FDA misses these goals, and what does it mean to patients?

I urge my colleagues, don't make this mistake. I know there is great pressure to do Build Back Better. But this is not the right bill.